Can an animal health company cut back on expenses by cutting back on animal testing? California's Kindred Biosciences ($KIN) is set to ramp up its operations by doing exactly that. The company will reformulate drugs already approved for humans and market them for pets, and expects FDA approval for three drugs for dogs by the end of the year. Kindred this week reported its Q1 earnings and announced it's on track with its CereKin pivotal study, its doggy drug for osteoarthritis, based off studies for Amgen ($AMGN) and Pfizer's ($PFE) Enbrel. Release